| Description | This product is a human neutralizing antibody which binds SARS-CoV-2 Spike S1, named CS23 (VH3-53 mAb). It targets the RBS of wildtype RBD through a canonical mode that is highly sensitive to the K417N mutation. CS23 is a neutralizing antibody effective against SARS-CoV-2 Beta variant. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Cross Reactivity | Beta, Gamma, Omicron |
| Epitope | It targets the RBS of wildtype RBD through a canonical mode. |
| Affinity | < 100 nM |
| Isotype | Human IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; SPR; BLI; Neut |
| Application Notes | This antibody was detected by ELISA, Surface plasmon resonance (SPR), Bio-layer interferometry (BLI) and Neutralization assay. ELISA: mAbs was tested at 100 ng/ml for binding to RBD Beta, wildtype RBD as well as RBD variants. Surface plasmon resonance (SPR): Purified mAbs were reversibly immobilized via the anti-human IgG capture surface. Bio-layer interferometry (BLI): IgG was diluted with kinetic buffer (1x PBS, pH 7.4, 0.01% BSA and 0.002% Tween 20). Neutralization assay (Neut): The mAbs was diluted 1:10 with sample dilution buffer, mixed 1:1 with wildtype HRP-RBD or Beta HRP-RBD solution and incubated at 37°C for 30 minutes. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 S1 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
